LMB vs NBIX · P/E 30, rev $312.3M vs P/E 45, rev $1.77B
Limbach Holdings Inc (LMB) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Limbach Holdings Inc (LMB) is a building products & equipment company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LMB revenue for 2026-06-30 was $312.3M. Net income was $9.1M. LMB currently screens at market cap $976.2M and trailing P/E 29.9.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
LMB currently screens at market cap $976.2M and trailing P/E 29.9. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the LMB and NBIX stock pages for the full models.
Not investment advice.